- Unii-U2Y5ofn795
-
- $0.10 / 1KG
-
2019-12-25
- CAS:649735-63-7
- Min. Order: 1KG
- Purity: 95%-99%
- Supply Ability: 1kg; 100kg; 1000kg
|
| | Brivanib alaninate Basic information |
| Product Name: | Brivanib alaninate | | Synonyms: | L-Alanine (1R)-2-[[4-[(4-fluoro-2-Methyl-1H-indol-5-yloxy)]-5-Methyl-1H-pyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]isopropyl ester;(2R)-1-({4-[(4-fluoro-2-Methyl-1H-indol-5-yl)oxy]-5-Methylpyrrolo[2,1-f][1,2,4]triazin-6-yl}oxy)propan-2-yl (2S)-2-aMinopropanoate;Brivanib alaninate BMS-540215;(1R)-2-((4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)oxy)-1-methylethyl L-alanine ester Brivanib alaninate (BMS-582664);Bms 582664;Bms582664;Brivanib alaninate;L-Alanine, (1R)-2-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-5-methylpyrrolo(2,1-F)(1,2,4)triazin-6-yl)oxy)-1-methylethyl ester | | CAS: | 649735-63-7 | | MF: | C22H24FN5O4 | | MW: | 441.46 | | EINECS: | | | Product Categories: | Inhibitors;Anti-cancer & immunity;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 649735-63-7.mol |  |
| | Brivanib alaninate Chemical Properties |
| density | 1.42±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | ≥22.05 mg/mL in DMSO; insoluble in H2O; ≥10.03 mg/mL in EtOH | | form | Yellow powder. | | pka | 16.08±0.30(Predicted) |
| | Brivanib alaninate Usage And Synthesis |
| Uses | BMS-582664 is an oral VEGFR/FGFR inhibitor for VEGFR2, Flk1, VEGFR1 and FGFR1 with IC50 of 25 nM, 89 nM, 380 nM and 148 nM, respectively. | | Uses | A novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor. | | Definition | ChEBI: Brivanib alaninate is a carboxylic ester resulting from the formal condensation of the carboxy group of L-alanine with the hydroxy group of brivanib. It is a prodrug of brivanib (BMS-540215), a potent oral dual inhibitor of VEGFR-2 and FGFR-1 (IC50 of 25 nM and 148 nM, respectively) and was in development for the treatment of hepatocellular and colon carcinomas. It has a role as an antineoplastic agent, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a prodrug, an apoptosis inducer, a fibroblast growth factor receptor antagonist and an angiogenesis inhibitor. It is a pyrrolotriazine, an aromatic ether, a fluoroindole, a diether, a carboxylic ester and a L-alanine derivative. It is functionally related to a brivanib. | | target | VEGFR2 |
| | Brivanib alaninate Preparation Products And Raw materials |
|